SunTech Medical, the leading provider of clinical-grade blood pressure monitoring solutions, and Valencell, a maker of accurate biometric sensors for wearables, have announced a partnership agreement to jointly develop new blood pressure measurement solutions that will enhance patient safety.
This multi-year agreement will allow the companies to work together to develop customized solutions and products for other medical device OEMs, as well as allowing SunTech to incorporate Valencell technology in its finished, branded products, says a press release.
Through this partnership SunTech’s Advantage™ cuff-based blood pressure technology, and its superior TMT (Transport Motion Tolerance) capabilities, will be combined with continuous BP estimation from Valencell’s optical PPG (photoplethysmography) technology, in order to provide a new and better BP measurement solution for higher acuity market segments like hemodialysis, emergency medicine, OR and ICU, ambulatory BP studies and cardiac rehabilitation, and sleep.
“The combination of multiple motion-tolerant technologies and measurement modalities from SunTech and Valencell will enable comfortable, continuous, clinical-grade BP monitoring for many applications,” said Paul Matsumura, SunTech’s Senior Director of Research and Technology about how the technologies could work in concert. “SunTech and Valencell are each the best in their field of motion tolerant blood pressure and PPG technology, respectively. Both together is a winning combination in the clinical space,” said Julian Mullaney, SunTech’s Vice President of R&D about the deal.
“We’re very pleased that two leading medical technology firms in North Carolina could come together to create new blood pressure solutions that will improve patient care and safety,” said Rob Sweitzer, SunTech’s President. “The Valencell team is exceptional, and as they engage with the clinical-grade blood pressure experts at SunTech, I’m certain together they’ll develop great new products for our customers. We look at this agreement as a framework to innovate with them long into the future.”
Valencell’s CEO Kent Novak said, “This collaboration agreement with SunTech sets the stage for some very exciting work together. Our teams each bring tremendous experience, expertise and technology from our respective domains. Establishing this long term agreement with SunTech helps accelerate the joint innovations that will have meaningful impacts on the market and more importantly on patient outcomes.”